Immune Checkpoint Inhibitors and EGFR-TKIs as Adjuvant/neoadjuvant Therapies for Resectable Non-small Cell Lung Cancer

Résumé du livre

The ESP Coordinating Center (ESP CC) is responding to a request from the VA National Oncology Program Office for a synthesis of evidence on the efficacy and safety of immune checkpoint inhibitors (ICIs) and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) as adjuvant or neoadjuvant therapies for resectable non-small cell lung cancer (NSCLC), which is intended to inform the VHA's Oncology Clinical Pathways.